Osteopontin expression in plasma of melanoma patients and in melanocytic tumours
Journal of the European Academy of Dermatology and Venereology, 08/17/2012
Maier T et al. – Osteopontin (OPN) seems to be a promising novel biomarker for the detection of metastatic disease in melanoma patients, showing elevated plasma levels in metastatic disease and increased protein expression in melanocytic lesions. The combination of OPN with the well–established tumour marker S100 might increase the prediction of metastases.